CytoDyn Inc. CYDY
OTC PK
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.06M | 2.28M | 1.65M | 1.80M | 1.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.58M | 6.80M | 6.30M | 5.10M | 4.95M |
| Operating Income | -6.58M | -6.80M | -6.30M | -5.10M | -4.95M |
| Income Before Tax | -19.94M | -9.86M | -4.69M | -22.61M | -5.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.94M | -9.86M | -4.69M | -22.61M | -5.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.94M | -9.86M | -4.69M | -22.61M | -5.54M |
| EBIT | -6.58M | -6.80M | -6.30M | -5.10M | -4.95M |
| EBITDA | -6.56M | -6.79M | -6.30M | -5.10M | -4.94M |
| EPS Basic | -0.01 | -0.01 | 0.00 | -0.02 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.02 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.38B | 1.37B | 1.28B | 1.26B | 1.25B |
| Average Diluted Shares Outstanding | 1.38B | 1.37B | 1.28B | 1.26B | 1.25B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |